Biotage issues further 3.4 million new shares

On June 30, 2005, the board of Biotage AB decided to increase the company’s share capital by means of a new issue of 3.4 million shares. The shares are subscribed by Carnegie Investment Bank for resale to a limited number of institutional investors in Sweden and abroad. The decision is based on the authorization to the board by the annual general meeting held on April 27, 2005. Through the present new issue and the new issue of 3 million shares that the board decided on June 27, 2005, the aforementioned authorization has been fully utilized by the board. By the new issue, the share capital is increased by SEK 3.4 million to SEK 70,442,108. The issue price amounts to SEK10.00 per share, corresponding to approx. 95.7 percent of the average volume weighted price paid for the Biotage share on June 30, 2005, and approx. 97.3 percent of the average volume weighted price paid for the share during the ten latest trading days (i.e. June 16 – 30, 2005). When calculating the average volume weighted price paid for the share during the ten latest trading days, the new issue of 3 million shares decided by the board on June 27, 2005, has not been taken into account The new shares correspond to approx. 4.8 percent of the capital and votes of Biotage following the issue. After deduction of costs, the new share issue brings the company new capital amounting to approx. SEK 33 million. The motive for the issue and the deviation from the shareholders’ preemption rights is – like the new issue decided by the board on June 27, 2005 – to promptly and efficiently finance a part of the acquisition of Argonaut’s business. Contact: Jeff Bork, President and CEO Tel: +46 734 22 16 60, jeff.bork@biotage.se Certain statements in this press release are forward-looking. These may be identified by the use of forward- looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward-looking statements are based on Biotage’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage’s products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.